Sequana Medical NV

Did you miss our KOL webcast? Check out the insightful discussion amongst Dr Saab, David Geffen School of Medicine, UCLA & Dr Pagadala, Methodist Dallas Medical Center, alongside #SequanaMedical management. ??? Watch on demand to catch up on the webinar and Q&A which explored the clinical need in recurrent and refractory #ascites due to #livercirrhosis, results of the alfapump POSEIDON and Patient Preference studies, in addition to alfapump US commercial roll-out plans and market opportunity. Click the link in the comments section below to view. #alfapump #transforminglives #cirrhosis

Register now for today’s KOL webcast! Join Dr Saab, David Geffen School of Medicine, UCLA & Dr Pagadala, Methodist Dallas Medical Center, alongside #SequanaMedical management discussing the results of the alfapump POSEIDON and Patient Preference studies, alfapump US commercial roll-out plans and market opportunity, and more. ?? Wednesday, January 8th, 2025, at 15:00 CET / 09:00 EST. Register using the link in the comments below. #alfapump #transforminglives #cirrhosis #ascites?

?? PRESS NEWS We are proud to announce that six-month data from the alfapump? pivotal POSEIDON study has been published in the prestigious peer-reviewed American Journal of Gastroenterology. This marks another milestone in the development of the alfapump. ?? Key highlights (1) ?? The alfapump? system effectively controls ascites in patients with decompensated cirrhosis, significantly reducing or even eliminating the need for therapeutic paracentesis. ?? Patients experienced a marked improvement in quality of life, gaining an additional 10 good health days per month. ?? Safety events were consistent with expectations for this patient population. ?? Overall survival of alfapump? patients surpassed that reported for standard care and was comparable to TIPS. With US PMA approval secured in December 2024, we are now gearing up for a US commercial launch in the second half of 2025. Learn more about this study and the impactful results here: https://lnkd.in/erH4Gjzr (1)??See press release for references and sources : https://lnkd.in/e2-sHWXC #alfapump #POSEIDON #HEPATOLOGY #LiverDisease #Ascites #CIRRHOSIS #ASCITES

please join this webinar on Wednesday January 8th at 3pm CET / 9am EST where Sequana Medical management will be joined by two leading KOLs. Together we will discuss the treatment landscape for recurrent and refractory #ascites due to liver #cirrhosis, how the #alfapump addresses unmet clinical needs, what the results of our POSEIDON pivotal study mean for US patients and physicians, and our plans for US commercial roll-out

Join our webcast tomorrow where #SequanaMedical management and KOLs will discuss US commercial roll-out following the FDA approval of alfapump? in December 2024 for the treatment of recurrent or refractory #ascites due to #livercirrhosis. ?? Wednesday, January 8th, 2025, at 15:00 CET / 09:00 EST The webinar will feature insights on the clinical need in recurrent and refractory #ascites due to #livercirrhosis, as well as the results of the alfapump POSEIDON and Patient Preference studies, and what this means for US patients and physicians. Dr Saab, David Geffen School of Medicine, UCLA & Dr Pagadala, Methodist Dallas Medical Center will be providing their perspectives on these topics. Click the link in the comments below for webinar registration. #alfapump #transforminglives #cirrhosis #ascites?

Did you miss our CEO, Ian Crosbie, on #OptimumTV? ??? ? Watch the video below to find out more about #alfapump, the first US approved active implantable medical device that automatically and continuously removes #ascites from the abdomen into the bladder. ? Following the exciting news of the US FDA approval of alfapump? for the treatment of recurrent or refractory #ascites due to #livercirrhosis, our CEO, Ian Crosbie, reflects on the significance of this milestone for #SequanaMedical. ? Find out how we are bringing the alfapump? to patient communities with US commercial launch planned for H2 2025 in the press release linked in the comments below. ? ??? Join our KOL webcast on Wednesday 8 January at 15:00 CET/09:00 ET. Click the link here for webcast registration: https://bit.ly/4gN61Lp?? ? #alfapump #transforminglives ? Read the full press release via the link in the comments below.

Thank you to Shani Alexander for a great article covering Sequana Medical NV recent FDA approval announcement for its alfapump and the impact this will have on the quality of life for patients with recurrent or refractory ascites due to liver cirrhosis. #alfapump #transforminglives

Thank you to Robert Barrie for featuring Sequana Medical NV FDA approval of our alfapump? device, which removes excess fluid that’s built up in the abdominal cavity, typically due to hashtag #liver disease. https://lnkd.in/e7k9V9Rq

??? Hear from our CEO, Ian Crosbie, on #OptimumTV where he discusses the US FDA approval of alfapump? for the treatment of recurrent or refractory #ascites due to #livercirrhosis! ? ?? Watch the full video below as Ian highlights this major milestone news for #SequanaMedical and learn more about #alfapump, the first US approved active implantable medical device that automatically and continuously removes #ascites from the abdomen into the bladder. ? Read the full press release via the link in the comments below.

?? #SequanaMedical receives US FDA approval of alfapump? for the treatment of recurrent or refractory #ascites due to #livercirrhosis! ?? We are proud to announce today that we have achieved a major milestone for the company – PMA Approval for the alfapump, alongside the existing FDA Breakthrough Device Designation. alfapump is the first US approved active implantable medical device that automatically and continuously removes ascites from the abdomen into the bladder. Our CEO, Ian Crosbie, commented on this exciting news: "With a standard of care that has seen minimal change in thousands of years, today marks a huge milestone for the large and growing liver ascites community in the US. Our vision is to transform the lives of these patients. “Recurrent or refractory liver ascites is a devastating condition with a terrible impact on the lives of our patients and their caregivers, not only for the painful and burdensome paracentesis procedure itself but also in the weeks leading up to each drainage. “The POSEIDON clinical study results demonstrate that the alfapump can virtually eliminate the need for therapeutic paracentesis, and improve patient quality of life, with a safety profile comparable to standard of care, delivering a twenty-first century solution that can allow these patients to take back their lives [1]. “We wish to thank all the patients and investigators who made this possible by participating in the POSEIDON study. With over 1,000 alfapump systems implanted to date, we look forward to starting commercialisation in H2 2025, bringing this innovative solution to many more patients in need.” Discover more about the alfapump in the press release linked in the comments below as we prepare for US commercial launch in H2 2025. Join our KOL webcast on Wednesday 8 January, 2025 at 15:00 CET/09:00 ET. Click the link here for webcast registration: https://bit.ly/4gN61Lp ? #alfapump #transforminglives #cirrhosis [1] POSEIDON study results in SSED (PMA P230044, FDA approval letter on file) – 100% median reduction in number of therapeutic paracentesis per month in Pivotal Cohort; Quality of life as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q)